On August 30, Genzyme Corp. declined to go ahead with the Sanofi-Aventis AG’s acquisition bid of $18.5 billion or $69-a-share, as the Company undervalued the worth of the former.

In a letter to Sanofi, Henri A. Termeer, Genzyme’s Chief Executive said, “The Genzyme board is not prepared to engage in merger negotiations with Sanofi based upon an opportunistic proposal with an unrealistic starting price that dramatically undervalues our company’’.

Trastuzumab-DM1 (T-DM1), a drug developed by Roche Holding AG, Swiss drug manufacturer, which is the first of its kind treatment that can contract tumours in HER2-positive breast cancer patients, is seeking approval from the Food and Drug Administration (FDA).

The Company submitted its application, along with the drug’s results from its Phase 2 trials to FDA, last month. Meanwhile, the phase 3 trials of the drug i.e. the first conjugated monoclonal antibody have been going on.

Pharmaceuticals Company ProStrakanis has a lot of hopes adhered to its anti-vomiting patch that it expects to starts retailing before the year-end. The firm speculates to fetch sales of up to $100 million (£64m) in the United States for its new patch.

However, the Company fears that its new patch may have the same destiny as that of Abstral in America.

The drug, which is already being retailed in Europe, had to face delay following the US Food & Drug Administration ruling of a three month extension in the review of the medicine.

Vertex Pharma Inc. on Tuesday informed that one of the studies depicted that extended treatment with hepatitis C drug candidate, telaprevir, helped in fetching positive results for some patients.

The pharma firm said that patients, quite quickly responded to treatment after they had been given telaprevir that showed better results after 24 weeks of the given therapy. But it also said that there were no other benefits at extending the therapy to a term of 48 weeks.

Further negotiations will be carried out by the Genzyme Corp., a world renowned maker of medicines for genetic diseases with French drug maker Sanofi-Aventis SA, on the proposal of acquisition offered by the latter, as told by some sources.

Yesterday, the two parties met to discuss their plan and proceedings.

The people related with the matter told that the executives of Genzyme Corp. want to have talks with Sanofi to revise the offer to $80 per share from an offer of $67 to $70 a share.

Charles River Laboratories International Inc. is reported to have abandoned its plans to acquire WuXi PharmaTech Inc., the Chinese drug testing Company under a deal worth $1.6 billion. The decision made by the Company is cited to be triggered by the agitation exhibited by its shareholders.

The Company dealing with laboratory rodents and facilitating animal testing for the pharmaceutical industry was in plans to widen its footprints by the acquisition deal, deemed to be the largest in the firm’s 63-year history.

It must have been a feeling of deja vu for Eli Lilly. It was the same courtroom and the lawyers were arguing on the same legal topics. After facing charges related to exclusive rights related to drugs, the company is involved in another such case.

This time around it is facing charges on the medicine that contributes heavily to its income.

A panel in the US Court of Appeals has given the ruling that a key patent related to Lilly's Gemzar is invalid.

Subsequent to market conjectures that Sanofi-Aventis is keen on acquiring the biotechnology firm, Genzyme, shares of Genzyme Corp. saw a surge on Monday.

While, spokespersons from both the parties refused to say anything, persons having knowledge about the matter revealed that Sanofi-Aventis made an unofficial offer to acquire Genzyme, according to reports by Wall Street Journal, on Friday.

Meanwhile, it is heard that other big drug makers like GlaxoSmithKline, Johnson & Johnson, are also showing interest in Genzyme.

Soon, the first generic version of blood thinner Lovenox will be launched by the German drug maker Sandoz and Momenta Pharmaceuticals Inc. after Food and Drug Administration approved their application on Friday.

FDA on the other hand, snubbed the argument put forth by the Sanofi-Aventis, the maker of Lovenox that their drug is very complicated for precise replication by other drug makers.

GlaxoSmithKline is facing hard days in its second quarter. The company has set aside a sum of 1.57 billion-Pound, in order to compensate with the legal charges inflicted on it, which claims that the drug Avandia, produced by the company, poses side effects such as heart attacks.

The legal charges against the company include product-liability and antitrust cases concerning Paxil antidepressant, lawsuits against Avandia and other products. After deduction of the tax, the charge cost around 1.35 billion Pounds.

French drug manufacturer, Sanofi-Aventis is eyeing a number of acquisitions in the U. S., which includes one or two that could be worth no less than $15 billion, a source familiar with the state of affairs said on Friday.

Shares of pharmaceutical stocks, including Biogen Idec Inc, Botox maker, Allergan Inc and Genzyme Corp, shot up on Friday on speculation that they might be the targets for Sanofi.

Biogen increased by 5%, Genzyme jumped up by 6% and Allergan was successful in gained 6%.

Shares in British drug company AstraZeneca jumped more than 10 per cent to £31.77 after a US court ruled that a patent on cholesterol drug Crestor was valid.

The Crestor was challenged by nine generic drug-makers in 2007. But, the US District Court in Delaware favored AstraZeneca by describing the patent as “valid & enforceable”.

The ruling has provided AstraZeneca with monopoly over producing and selling Crestor as cheaper, generic versions of the drug now can not enter the US market until 2016.

According to Citi estimates, Crestor accounts for 20 per cent of group profits.

Celgene is going to acquire Abraxis BioScience, one of world's leading pharmaceutical company in a deal worth $2.9 billion, which will see the latter offering cash as well as stocks value.

Abraxis BioScience Chief Executive, Patrick Soon-Shiong, is going to handover the assets worth $4 billion to Celgene.

Dr. Soon-Shiong, 57, who is a surgeon, possesses 82.4% stake in the Company.

He has been identified as one of the most affluent executives in the nation. His patients travel from overseas to get treatments.

Walgreen Co., which is the largest U. S. drugstore chain, informed about a lower-than-anticipated quarterly profit as sales of nonprescription items saw low demand, sending its shares down by 6.1%.

Sales at stores open at least a year, which did not include its getting hold of Duane Reade, which increased by 0.7% in general, but inched up by a mere 0.1% in common, or front-end, merchandise such as milk, aspirin, toothpaste and cosmetics, because of weak discretionary spending and lower demand for flu-related products.

The cannabis-based drug Sativex, has been discovered for treating symptoms of multiple sclerosis, and has now been approved in Britain on Friday, the same has lifted the GW Pharma's shares by 11pc to a four-year high of
141p.

According to the GW Pharma, the drug which shall be sold in Britain by the licensee Bayer which shall cost the National Health Service £125 for a 10 mililitre vial which shall be enough to last for an average patient for 11 days.